Vaccine Tested on Humans, May Stop 90 Percent of Cancers

Publish date:

ImMucin, a vaccine, developed by drug company Vaxil Biotheraputics along with researchers at Tel Aviv University in Israel, can reportedly train cancer patients' own bodies to find and destroy tumor cells.

The vaccine has been tested on humans for the first time. According to The Daily Mail, "the results from that safety trial -- on patients with blood cancer -- found all had greater immunity to the disease after receiving the vaccine. Three of the seven patients who have completed the treatment are now free of the condition."

A statement from Vaxil Biotheraputics said: "ImMucin generated a robust and specific immune response in all patients which was observed after only 2-4 doses of the vaccine out of a maximum of 12 doses. In some of the patients, preliminary signs of clinical efficacy were observed."

The vaccine, which targets MUC1 (a molecule found in 90 per cent of all cancers), could provide a universal injection that allows patients' immune systems to fight off common cancers including breast and prostate cancer.

The scientists, behind the vaccine, believe it could be used to combat small tumors if they are detected early enough or to help prevent the return and spread of disease in patients who have undergone other forms of treatment such as surgery.

Cancer cells usually evade patient's immune systems because they are not recognized as being a threat, like bacteria is.

One very dangerous type of cancer cell is lymphoma. Read more about the symptoms of lymphoma.


Popular Video